Überblick zur Supportivtherapie für Patienten mit Kopf-Hals-Tumoren ^[*]

Zusammenfassung

Fragestellung Es sollen die spezifischen Aspekte der Supportivtherapie bei Kopf-Hals-Karzinomen zusammengestellt werden.

Methode Darstellung der Symptome entsprechend des Zeitverlaufs der Behandlung. Supportive Therapieansätze entsprechend der S3-Leitlinie und Ansätze aus der Komplementärmedizin werden zugeordnet.

Ergebnisse Die Patienten erleben Funktionsverluste durch ihre Krankheit und die erfahrene Therapie. Im Vordergrund stehen dabei die Beeinträchtigungen der Stimme und Sprache sowie der Nahrungsaufnahme. Ästhetische Probleme, weitere Sinnesverluste (Riechen, Schmecken, Hören) und Komorbiditäten (insbesondere im psychiatrischen Bereich) prägen den Alltag unserer Patienten.

Schlussfolgerung Der multimodalen Behandlung eines fortgeschrittenen Kopf-Hals-Tumors muss eine multiprofessionelle Supportivmedizin entgegengesetzt werden, die für diese Patienten oft lebenslang notwendig ist.

Abstract

Objective We summarize the specific aspects of supportive care for patients with head and neck cancers.

Methods Along the course of disease we describe the typical symptoms of these patients. Therapeutic approaches were added according to the German guideline for supportive care and experiences of CAM.

Results The patients experience losses of several functions as a result of cancer disease and cancer therapy. The main fields are deficits in voice/speech and nutrition/swallowing. Aesthetic problems, further loss of senses (smell, taste, hearing) and co-morbidities (psychiatric diseases) are typical for the daily life of our patients.

Conclusion Multimodal cancer treatment has to be accompanied by multiprofessional supportive care. This specific life-long support is necessary for the majority of head-and-neck cancer survivors.

Schlüsselwörter

Kopf-Hals-Tumoren - Einschränkungen - supportive Behandlungsansätze - Komplementärmedizin

Key words

Head and neck cancer - deficits - supportive care approaches - complementary medicine

^* In Erinnerung an unseren Kollegen Dr. med. Robert Hunger-Schmid, Internist und Hausarzt in Chur

Publication History

Article published online:
17 September 2021

• Literatur

• 1 Leitlinienprogramm Onkologie: Supportive Therapie. Im Internet: https://www.leitlinienprogramm-onkologie.de/leitlinien/supportive-therapie/; Stand: 25.06.2021
• 2 Guntinas-Lichius O, Wendt T, Buentzel J. et al Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database. J Cancer Res Clin Oncol 2010; 136: 55-63 DOI: 10.1007/s00432-009-0636-y.
• 3 Kochhar A, Larian B, Azizzadeh B. Facial Nerve and Parotid Gland Anatomy. Otolaryngol Clin North Am 2016; 49: 273-284 DOI: 10.1016/j.otc.2015.10.002.
• 4 Paleri V, Wight RG, Silver CE. et al Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice. Oral Oncol 2010; 46: 712-719 DOI: 10.1016/j.oraloncology.2010.07.008.
• 5 Ickenstein GW, Riecker A, Höhlig C. et al Pneumonia and in-hospital mortality in the context of neurogenic oropharyngeal dysphagia (NOD) in stroke and a new NOD step-wise concept. J Neurol 2010; 257: 1492-1499 DOI: 10.1007/s00415-010-5558-8.
• 6 Kondrup J, Allison SP, Elia M. et al ESPEN guidelines for nutrition screening 2002. Clin Nutr 2003; 22: 415-421 DOI: 10.1016/s0261-5614(03)00098-0.
• 7 Büntzel J, Micke O, Kisters K. et al Malnutrition and survival – bioimpedance data in head neck cancer patients. In Vivo 2019; 33: 979-982 DOI: 10.21873/invivo.11567.
• 8 Zhao SG, Alexander NB, Djuric Z. et al Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial. Head Neck 2016; 38: E1086-E1096 DOI: 10.1002/hed.24162.
• 9 Govender R, Smith CH, Taylor SA. et al Swallowing interventions for the treatment of dysphagia after head and neck cancer: a systematic review of behavioural strategies used to promote patient adherence to swallowing exercises. BMC Cancer 2017; 17: 43 DOI: 10.1186/s12885-016-2990-x.
• 10 Mueller SA, Mayer C, Bojaxhiu B. et al Effect of preoperative immunonutrition on complications after salvage surgery in head and neck cancer. J Otolaryngol Head Neck Surg 2019; 48: 25 DOI: 10.1186/s40463-019-0345-8.
• 11 Bianchini C, Malagò M, Crema L. et al Post-operative pain management in head and neck cancer patients: predictive factors and efficacy of therapy. Acta Otorhinolaryngol Ital 2016; 36: 91-96 DOI: 10.14639/0392-100X-499.
• 12 Braga M, Ljungqvist O, Soeters P. et al ESPEN Guidelines on Parenteral Nutrition: surgery. Clin Nutr 2009; 28: 378-386 DOI: 10.1016/j.clnu.2009.04.002.
• 13 Pfirrmann D, Simon P, Mehdorn M. et al Präkonditionierung vor viszeralonkologischen Operationen. Chirurg 2018; 89: 896-902 DOI: 10.1007/s00104-018-0709-z.
• 14 Clarke P, Radford K, Coffey M. et al Speech and swallow rehabilitation in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016; 130: S176-S180 DOI: 10.1017/S0022215116000608.
• 15 Valentini V, Marazzi F, Bossola M. et al Nutritional counselling and oral nutritional supplements in head and neck cancer patients undergoing chemoradiotherapy. J Hum Nutr Diet 2012; 25: 201-208 DOI: 10.1111/j.1365-277X.2011.01220.x.
• 16 Fatima T, Haji Abdul Rahim ZB, Lin CW. et al Zinc: A precious trace element for oral health care. J Pak Med Assoc 2016; 66: 1019-1023
• 17 Bruns F, Büntzel J, Mücke R. et al Selenium in the treatment of head and neck lymphedema. Med Princ Pract 2004; 13: 185-190 DOI: 10.1159/000078313.
• 18 Büntzel J, Hübner J, Büntzel J. Komplementärmedizinische Behandlungsansätze bei oraler Mukositis und Xerostomie. Onkologe 2019; 25: 269-274 DOI: 10.1007/s00761-019-0521-5.
• 19 Münstedt K, Momm F, Hübner J. Honey in the management of side effects of radiotherapy- or radio/chemotherapy-induced oral mucositis. A systematic review. Complement Ther Clin Pract 2019; 34: 145-152 DOI: 10.1016/j.ctcp.2018.11.016.
• 20 Büntzel J, Riesenbeck D, Glatzel M. et al Limited effects of selenium substitution in the prevention of radiation-associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Res 2010; 30: 1829-1832
• 21 Büntzel J, Micke O, Kisters K. et al Selenium substitution during radiotherapy of solid tumours - laboratory data from two observation studies in gynaecological and head and neck cancer patients. Anticancer Res 2010; 30: 1783-1786
• 22 Hoppe C, Kutschan S, Dörfler J. et al Zinc as a complementary treatment for cancer patients: a systematic review. Clin Exp Med 2021; 21: 297-313 DOI: 10.1007/s10238-020-00677-6.
• 23 Bensadoun R-J, Nair RG. Low-level laser therapy in the prevention and treatment of cancer therapy-induced mucositis: 2012 state of the art based on literature review and meta-analysis. Curr Opin Oncol 2012; 24: 363-370 DOI: 10.1097/CCO.0b013e328352eaa3.
• 24 Buentzel J, Welgemoed H, Bensadoun R-J. Prevention of Toxicities by Cytoprotection: The Role of Amifostine in the Supportive Care of Cancer for Patients with Head and Neck Cancer. www.smgebooks.com. 2016
• 25 Cady J. Nutritional support during radiotherapy for head and neck cancer: the role of prophylactic feeding tube placement. Clin J Oncol Nurs 2007; 11: 875-880 DOI: 10.1188/07.CJON.875-880.
• 26 Friedes C, Klingensmith J, Nimo N. et al Late feeding tube dependency in head and neck cancer patients treated with definitive radiation therapy and concurrent systemic therapy. Cureus 2020; 12: e7683 DOI: 10.7759/cureus.7683.
• 27 Guigay J, Tahara M, Licitra L. et al The evolving role of taxanes in combination with cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: evidence, advantages, and future directions. Front Oncol 2019; 9: 668 DOI: 10.3389/fonc.2019.00668.
• 28 Aapro MS, Bohlius J, Cameron D. et al 2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47: 8-32 DOI: 10.1016/j.ejca.2010.10.013.
• 29 Kaushal J, Gupta MC, Kaushal V. et al Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. Singapore Med J 2010; 51: 871-875
• 30 Ezzo JM, Richardson MA, Vickers A. et al Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. Cochrane Database Syst Rev 2006: CD002285. doi:10.1002/14651858.CD002285.pub2
• 31 Marx W, Ried K, McCarthy AL. et al Ginger – mechanism of action in chemotherapy-induced nausea and vomiting: A review. Crit Rev Food Sci Nutr 2017; 57: 141-146 DOI: 10.1080/10408398.2013.865590.
• 32 Gurney JG, Bass JK, Onar-Thomas A. et al Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro-oncology 2014; 16: 848-855 DOI: 10.1093/neuonc/not241.
• 33 Ghorbani A. Renal protective effect of selenium on cisplatin-induced nephrotoxicity. J Renal Inj Prev 2012; 1: 31-32 DOI: 10.12861/jrip.2012.11.
• 34 Hwang M, Seiwert TY. Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era. Lancet Oncol 2021; 22: 413-415 DOI: 10.1016/S1470-2045(21)00121-2.
• 35 Macdonald JB, Macdonald B, Golitz LE. et al Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol 2015; 72: 203-218 quiz 219–220 DOI: 10.1016/j.jaad.2014.07.032.
• 36 Stintzing S, Fischhaber D, Mook C. et al Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels. Anticancer Drugs 2013; 24: 969-974 DOI: 10.1097/CAD.0b013e32836411bc.
• 37 Arzbach V. EGFR-Inhibitoren: Hautreaktionen kompetent managen. Pharmazeutische Zeitung online. Im Internet: https://www.pharmazeutische-zeitung.de/ausgabe-212012/hautreaktionen-kompetent-managen/; Stand: 25.06.2021
• 38 Selzer E, Liederer S, Lemaire C. et al Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab. Strahlenther Onkol 2011; 187: 373-377 DOI: 10.1007/s00066-011-2217-7.
• 39 Schrag D, Chung KY, Flombaum C. et al Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005; 97: 1221-1224 DOI: 10.1093/jnci/dji242.
• 40 Cohen EEW, Bell RB, Bifulco CB. et al The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer 2019; 7: 184 DOI: 10.1186/s40425-019-0662-5.
• 41 Büntzel J, Glatzel M, Mücke R. et al Influence of amifostine on late radiation-toxicity in head and neck cancer--a follow-up study. Anticancer Res 2007; 27: 1953-1956
• 42 Leitlinienprogramm Onkologie: Komplementärmedizin Im Internet: https://www.leitlinienprogramm-onkologie.de/leitlinien/komplementaermedizin/; Stand: 25.06.2021
• 43 Devi S, Singh N. Dental care during and after radiotherapy in head and neck cancer. Natl J Maxillofac Surg 2014; 5: 117-125 DOI: 10.4103/0975-5950.154812.
• 44 Smith BG, Lewin JS. Lymphedema management in head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 2010; 18: 153-158 DOI: 10.1097/MOO.0b013e32833aac21.
• 45 Korsten LHA, Jansen F, de Haan BJF. et al Factors associated with depression over time in head and neck cancer patients: A systematic review. Psychooncology 2019; 28: 1159-1183 DOI: 10.1002/pon.5058.
• 46 Vitek P, Koscielny S, Büssing A. et al Religiosität und Spiritualität als Ressourcen in der Betreuung von Patienten mit Kopf-Hals-Tumoren. Laryngorhinootologie 2021; DOI: 10.1055/a-1516-4589.
• 47 Strojan P, Hutcheson KA, Eisbruch A. et al Treatment of late sequelae after radiotherapy for head and neck cancer. Cancer Treat Rev 2017; 59: 79-92 DOI: 10.1016/j.ctrv.2017.07.003.
• 48 Bond SM, Dietrich MS, Shuster JL. et al Delirium in patients with head and neck cancer in the outpatient treatment setting. Support Care Cancer 2012; 20: 1023-1030 DOI: 10.1007/s00520-011-1174-0.